TREVIA R2 5+100MG Tablet is a combination medication that contains two active ingredients: Ertugliflozin and Sitagliptin. Ertugliflozin belongs to the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors, and Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. This combination is used to manage type 2 diabetes mellitus in adults to help control blood sugar levels.
- Type 2 Diabetes Mellitus Management: TREVIA R2 Tablet is prescribed to manage type 2 diabetes in adult patients. Ertugliflozin works by reducing the reabsorption of glucose by the kidneys, leading to increased glucose excretion through urine. Sitagliptin, on the other hand, helps regulate blood sugar levels by inhibiting the breakdown of incretin hormones, which stimulate insulin release after meals and reduce glucose production by the liver.
Like all medications, TREVIA R2 5+100MG Tablet may cause some side effects in certain individuals. Not everyone will experience these side effects, and their severity may vary. Common side effects of this combination may include:
- Urinary Tract Infections (UTIs): Ertugliflozin’s mechanism of action involves increased glucose excretion in the urine, which may raise the risk of UTIs.
- Genital Yeast Infections: Some patients may experience genital yeast infections due to the increased sugar content in the genital area caused by empagliflozin.
- Hypoglycemia: While Sitagliptin is less likely to cause hypoglycemia, combining it with Ertugliflozin may increase the risk of low blood sugar levels, particularly if used with other antidiabetic medications.
- Gastrointestinal Disturbances: Nausea, diarrhea, vomiting, and abdominal discomfort may occur in some patients.
- Increased Urination and Thirst: Ertugliflozin’s diuretic effect can lead to increased urination and thirst.
When Not to Use:
- Type 1 Diabetes: TREVIA R2 5+100MG Tablet is not suitable for the treatment of type 1 diabetes.
- Diabetic Ketoacidosis (DKA): This medication should not be used in patients with diabetic ketoacidosis, a severe condition characterized by high ketone levels in the blood.
- Severe Kidney Impairment: Individuals with severe kidney impairment or end-stage renal disease should avoid using this medication due to the risk of adverse effects on the kidneys.
- History of Allergic Reactions: If you have a history of hypersensitivity or allergic reactions to Ertugliflozin, Sitagliptin, or any other components of the tablet, you should not use TREVIA R2.
- Pregnancy and Breastfeeding: The safety of TREVIA R2 during pregnancy and breastfeeding has not been established. Consult your doctor before using this medication if you are pregnant or breastfeeding.
Always follow your healthcare provider’s instructions and never self-medicate. If you experience any severe or persistent side effects, contact your doctor immediately. Adjustments to your diabetes management plan may be necessary based on your individual response to the medication.